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Background
Mometasone furoate/formoterol (MF/F) combination
therapy is a new treatment for persistent asthma. We
report findings from a non-inferiority study that com-
pared effects of MF/F and fluticasone propionate/salme-
terol (FP/S) combination therapies on pulmonary
function and onset of action in subjects with persistent
asthma.
Materials and methods
This randomized, active-controlled, multicenter, non-
inferiority trial enrolled subjects (≥12 yrs) previously
treated with medium-dose inhaled corticosteroid alone
or combined with a long-acting b2-agonist. Following a
2-4 wk run-in treatment period with MF administered
via metered-dose inhaler (MDI) 200 μgt w i c ed a i l y
(BID), eligible subjects were randomized to MF/F-MDI
200/10 μg BID or FP/S administered via dry-powder
inhaler (DPI) 250/50 μg BID for 12 wks. The primary
e n d p o i n tw a sc h a n g ef r o mb a s e l i n ei na r e au n d e rt h e
c u r v ei nf o r c e de x p i r a t o r yv o l u m ei n1s0 - 1 2hp o s t -
dose (FEV1AUC0-12 h). Key secondary endpoints
included onset of action, defined as change from base-
line in FEV1 at 5 min postdose on Day 1.
Results
722 subjects were randomized to MF/F-MDI (n = 371)
or FP/S-DPI (n = 351). MF/F-MDI was found to be
non-inferior to FP/S-DPI for mean FEV1AUC0-12 h at
endpoint (3.43 vs 3.24 Lxh, respectively; 95% CI, -0.40,
0.76). MF/F-MDI’s onset of action was rapid and signifi-
cantly faster than observed for FP/S-DPI (Figure 1), with
a 200 mL mean increase from baseline in FEV1 at 5 min
postdose (first scheduledm e a s u r e m e n t )o nD a y1f o r
MF/F-MDI vs 90 mL for FP/S-DPI (P < 0.001).
Conclusions
This non-inferiority trial demonstrated that MDI-admi-
nistered MF/F 200/10 μg BID was non-inferior to DPI-
administered FP/S 250/50 μg BID in FEV1AUC0-12 h. MF/
F-MDI was superior to FP/S-DPI in onset of action.
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Figure 1 Onset of action for MF/F-MDI vs FP/S-DPI
combination therapies.
Bernstein et al. Allergy, Asthma and Clinical Immunology 2010, 6(Suppl 2):P33
http://www.aacijournal.com/content/6/S2/P33 ALLERGY, ASTHMA & CLINICAL 
IMMUNOLOGY
© 2010 Bernstein et al; licensee BioMed Central Ltd.Author details
1University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA.
2Boys Town National Research Hospital, Boys Town, NE, 68130, USA.
3Merck
Research Laboratories, Kenilworth, NJ, 07033, USA.
Published: 22 December 2010
doi:10.1186/1710-1492-6-S2-P33
Cite this article as: Bernstein et al.: Non-inferiority efficacy comparison
of mometasone furoate/formoterol versus fluticasone propionate/
salmeterol combination therapies in subjects with persistent asthma.
Allergy, Asthma and Clinical Immunology 2010 6(Suppl 2):P33.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bernstein et al. Allergy, Asthma and Clinical Immunology 2010, 6(Suppl 2):P33
http://www.aacijournal.com/content/6/S2/P33
Page 2 of 2